Leverage CHI's resources and content expertise for your in house training needs.  With over 20 years of experience in developing cutting edge content and programming, CHI is uniquely positioned to help you meet your in house training goals. LEVERAGE CHI's BASE

  Project Management Internal CHI Project Manager & Coordinator Manage Client CHI Communication Project and Time line Management Meeting Planning Logistics Hotel Site Selection Budget Management Meeting Room Site Logistics Food & Beverage Planning Audio Visual Management Security Negotiations &

  Outsource Your Conference, User Group Meeting or Roadshow to the CHI Team Cambridge Healthtech Institute (CHI) is a multi-media business servicing the life science industry. We produce over 100 conferences annually and are well-known for delivering strong scientific content, bringing together thought leader

  Having conducted over 500 interactive web seminars, Barnett is well-experienced in designing and delivering Web-based events that are highly interactive and engaging. Throughout our multi-year history with the platform, we have designed a methodology for developing, managing, providing technical support for

Value Proposition: Recognizing that clients are inundated with “traditional” marketing approaches such as e-mail, direct mail and sales calls, through its Barnett division, CHI has responded to our vendor clients with an all-new promotional platform that uses our expertise in educational content development

Author: Peter Norman, MBA, PhD

Diabetes Pipeline: Intense Activity to Meet Unmet Need examines agents currently in development for the treatment of diabetes and includes 50+ tables summarizing the activity in this product field. 

Key topics covered include:

·         Pros and cons of marketed therapies and global market snapshots

·         Development pipelines and approaches taken

·         Anticipated FDA filing dates for significant new products

·         Profiles of selected companies active in the field, including major and emerging players as well as specialist companies

·         Global market forecast to 2014, accounting for impacts of generics and new therapies

·         Expert interviews